Together these results are consistent with prior work suggesting changes in BOLD-LFOs are related to early AD pathophysiological changes on PET and CSF biomarkers and extend prior findings by demonstrating the relationship between decreased BOLD-LFOs and early stage plasma pTau217 in APOE4 carriers specifically. The gene discussed is APOE; the disease is Alzheimer disease.